Current reports
6-K
Condensed Interim Consolidated Financial Statements
6 Dec 23
6-K
Condensed Interim Consolidated Financial Statements
18 Aug 23
6-K
Condensed Interim Consolidated Financial Statements
31 May 23
6-K
Consolidated Financial Statements
4 May 23
6-K
Adastra Holdings Reports FY2022 Results; Demonstrating A Second Year of Record Revenue
4 May 23
6-K
Current report (foreign)
13 Apr 23
6-K
Current report (foreign)
20 Mar 23
6-K
Current report (foreign)
3 Mar 23
6-K
Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer's License
23 Feb 23
6-K
Current report (foreign)
15 Feb 23
Registration and prospectus
15-12G
Securities registration termination
1 May 24
D
$173.21K in options / securities to be acquired, 1 investor
6 Sep 22
20FR12G/A
Initial registration of securities (foreign private issuers) (amended)
18 Mar 22
20FR12G/A
Initial registration of securities (foreign private issuers) (amended)
11 Mar 22
20FR12G/A
Initial registration of securities (foreign private issuers) (amended)
18 Feb 22
20FR12G/A
Initial registration of securities (foreign private issuers) (amended)
21 Jan 22
20FR12G
Initial registration of securities (foreign private issuers)
8 Nov 21
Proxies
No filings
Other
UPLOAD
Letter from SEC
28 Mar 22
CORRESP
Correspondence with SEC
18 Mar 22
UPLOAD
Letter from SEC
16 Mar 22
CORRESP
Correspondence with SEC
11 Mar 22
UPLOAD
Letter from SEC
2 Mar 22
CORRESP
Correspondence with SEC
18 Feb 22
UPLOAD
Letter from SEC
7 Feb 22
CORRESP
Correspondence with SEC
20 Jan 22
UPLOAD
Letter from SEC
6 Jan 22